Novo Nordisk (NYSE:NVO) said this week that the CEO of Canadian biotech Novelion Therapeutics, Mary Szela, left Nordisk’s board effective immediately due to a “potential conflict of interest”. Szela’s departure follows Novelion’s decision to expand into non-alcoholic steatohepatitis, also known as fatty liver, according to a Nordisk spokeswoman. As the Danish drugmaker faces increasing pricing pressure […]
genoapharmaceuticals
Genoa raises $62m Series A for inhaled lung drug
Genoa Pharmaceuticals said today that it raised $62 million in a Series A round to support the development of inhaled therapies for idiopathic pulmonary fibrosis and other severe pulmonary conditions. The round was led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners. Novo AS, RiverVest Venture Partners and TPG Biotech also invested in […]